SCHEMBL15919442

SCHEMBL15919442

CC(=O)c1cnccc1NC(=O)c1ccc(Br)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.57
CYP11B2 P19099 1/20 0.57
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
RAB9A P51151 4/20 0.47
KDM4D Q6B0I6 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KDM4E B2RXH2 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
POLB P06746 2/20 0.45
NPC1 O15118 2/20 0.44
TP53 P04637 1/20 0.44
MAPK1 P28482 1/20 0.44
PKM P14618 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16334328 0.82 CYP11B1 (0.56) CYP11B1CYP11B2MEN1KMT2ARAB9A
SCHEMBL17624572 0.79 CYP11B1 (0.56) CYP11B1CYP11B2MEN1KMT2ARAB9A
SCHEMBL14542346 0.78 CYP11B1 (0.57) CYP11B1CYP11B2MEN1KMT2ARAB9A
SCHEMBL321601 0.77 CYP11B1 (0.56) CYP11B1CYP11B2MEN1KMT2ARAB9A
SCHEMBL31563528 0.74 KDM4C (0.59) KDM4CKDM4EL3MBTL1TDP1POLB
SCHEMBL12990781 0.74 KDM4C (0.59) KDM4CKDM4EL3MBTL1TDP1POLB
SCHEMBL22129133 0.74 CYP11B1 (0.60) CYP11B1CYP11B2MEN1KMT2ARAB9A
SCHEMBL6771981 0.73 SERPINE1 (0.60) RAB9AKDM4DKDM4CMAPTSMN1; SMN2
SCHEMBL6354168 0.73 CYP11B1 (1.00) CYP11B1CYP11B2MEN1KMT2ARAB9A
SCHEMBL6001715 0.73 POLB (0.68) MEN1KMT2ARAB9ASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO CYP11B1 353/4885CYP11B2 387/4885MEN1 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.